metformin / Generic mfg. - LARVOL DELTA

Phase I/Ib study of inavolisib (INAVO) alone and in combination with endocrine therapy ± palbociclib (PALBO) in patients (pts) with PIK3CA-mutated, hormone receptor–positive, HER2-negative locally advanced/metastatic breast cancer (HR+, HER2– LA/mBC): Analysis of hyperglycemia (HG) in prediabetic/obese pts. (ASCO 2025) - P1 | "Clinical Trial Registration Number: NCT03006172 Background: INAVO, a highly potent and selective PI3Kα inhibitor that also promotes degradation of mutated p110α, is approved by the FDA in combination with PALBO + fulvestrant (FULV) for PIK3CA-mutated, HR+, HER2–, endocrine-resistant advanced BC... Adults ≥ 18 years of age received INAVO alone (Arm A), + letrozole (LET) + PALBO (Arm B), + LET (Arm C), + FULV (Arm D), + FULV + PALBO (Arm E), or + FULV + PALBO + primary prophylactic metformin (Arm F)...The most common anti-HG medications were metformin (52.7%; biguanide; concomitant use in Arm F excluded), empagliflozin (25.5%; SGLT-2 inhibitor), sitagliptin (22.7%; DPP-4 inhibitor), and pioglitazone (13.6%; thiazolidinedione); insulin was used in 8.2% of pts... A high proportion of prediabetic/obese pts were included in GO39374. In most of these pts, HG was manageable with dose interruptions and oral anti-HG medications, most commonly metformin. Data support the use..."

Clinical • Combination therapy • Metastases • P1 data • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Obesity • Oncology • Solid Tumor • HER-2 • PIK3CA

Association of race and survival in patients treated with apalutamide: Pooled analysis of two phase 3 trials. (PubMed, Cancer) - "In this study, the authors did not find any evidence of difference in the treatment effect of apalutamide on OS across patients of different races, although interpretation remains limited by poor representation of racial minorities. Among apalutamide-treated patients, there was no association of race with OS."

Journal • P3 data • Retrospective data • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

Metformin Inhibits Non-Small Cell Lung Cancer via lncRP11-242D8.1. (PubMed, Arch Biochem Biophys) - "This study suggests that metformin treats NSCLC by upregulating lncRP11-242D8.1 expression, which inhibits inflammation and promotes apoptosis, offering a new perspective for clinical treatment."

Journal • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

Clinical efficacy of iGlarLixi in patients with T2DM combined with MASLD (ChiCTR) - P=N/A | N=25 | Completed | Sponsor: Drum Tower Hospital Affiliated to Nanjing University Medical School; Drum Tower Hospital Affiliated to Nanjing University Medical School

New trial • Diabetes • Hepatology • Metabolic Disorders • Metabolic Dysfunction-Associated Steatotic Liver Disease • Type 2 Diabetes Mellitus

DPP4 and Insulin Protein: Drug Targets for a Formulated Polyherbal Combination of Phyllanthus urinaria L. and Adhatoda vasica Nees Against HFD-STZ-Induced TIIDM in Swiss Albino Mice. (PubMed, Chem Biodivers) - "Okanin and vomicine, identified from LCMS analysis as potent antidiabetic bioactive compounds bind to dipeptidyl peptidase 4 (DPP4) with a binding energy of -8.04 and -7.81 kcal/mol, respectively, as compared to standard drug metformin (-5.33 kcal/mol). Inhibition of DDP-4 by bioactives of PHF aids in enhanced secretion of incretion hormones leading to insulin secretion thereby established itself as a complementary and alternative therapeutics in the management of diet-induced TIIDM."

Journal • Preclinical • Diabetes • Infectious Disease • Metabolic Disorders • Type 2 Diabetes Mellitus • IR • PDX1 • SLC2A4 • TCF7L2

Investigating the therapeutic effect of metformin on melanoma cancer stem cells using optical microscopy. (PubMed, Med Eng Phys) - "Our findings revealed that higher concentrations (24 mM) of metformin corresponded to a reduced number of cell spheres, consistent with results reported by other research groups. These observations suggest that optical microscopy is a viable technique for monitoring the short-term effects of metformin on melanoma CSCsin vitro."

Journal • Diabetes • Melanoma • Metabolic Disorders • Oncology • Solid Tumor • Type 2 Diabetes Mellitus

Phosphatidylserine liposomes containing metformin mitigate experimental atopic dermatitis: evidence for Akt/mTOR pathway involvement. (PubMed, Inflammopharmacology) - No abstract available

Journal • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Drug repurposing strategy to identify the putative leads against the Epidermal growth factor receptor (EGFR) from the USFDA-approved drug pool: Investigating the utility as an anticancer agent. (PubMed, J Mol Graph Model) - "The initial HTVS (high-throughput virtual screening), followed by XP analysis and molecular mechanics (MMGBSA) and ADME profiling, led to the identification of Cycloguanil (antimalarial) and Metformin (antidiabetic) as the putative lead molecules with the potential to inhibit the EGFR...Cycloguanil inhibited the EGFR with a half maximal inhibitory concentration (IC50) of IC50 of 490 nM compared to erlotinib with an IC50 of 222 nM...From the analysis, it was deduced that cycloguanil exhibited the most potent cytotoxicity towards the A549 cell with an IC50 of 6.83 μM, followed by HCT-116 with an IC50 of 9.32 μM, while in MCF-7, it exhibited an IC50 of 14.82 μM. The lead molecule, cycloguanil, may plausibly serve as an important template that may be optimized by performing bioisosteric replacements, leading to a putative kinase inhibitor with a potent anticancer profile."

FDA event • Journal • Infectious Disease • Oncology • ANXA5 • EGFR

A phase I study of temsirolimus in combination with metformin in patients with advanced or recurrent endometrial cancer. (PubMed, Gynecol Oncol) - P1 | "The results of this single-center clinical trial showed that, in patients with advanced or recurrent endometrial cancer, metformin can be safely added to temsirolimus providing limited response without added safety concerns."

Journal • P1 data • Anorexia • Dyslipidemia • Endometrial Cancer • Fatigue • Hematological Disorders • Hypertriglyceridemia • Mucositis • Oncology • Renal Disease • Solid Tumor • Thrombocytopenia

Metformin for patients with metastatic prostate cancer starting androgen deprivation therapy: a randomised phase 3 trial of the STAMPEDE platform protocol. (PubMed, Lancet Oncol) - P2/3 | "We did not find significant evidence of an overall survival benefit of adding metformin to standard of care in the overall population of patients with metastatic hormone-sensitive prostate cancer. The side-effect profile of metformin was as expected and consisted mainly of diarrhoea. Adverse metabolic side-effects of ADT were significantly reduced in the metformin group compared with the standard of care group."

Journal • P3 data • Genito-urinary Cancer • Hormone Sensitive Prostate Cancer • Oncology • Prostate Adenocarcinoma • Prostate Cancer • Solid Tumor

The interactions between autophagy and immune in the liver-adipose-ovary circuit of polycystic ovary syndrome. (PubMed, Front Immunol) - "Clinical therapies targeting this circuit (e.g., quercetin, metformin) show promise by regulating autophagy, improving insulin sensitivity, and restoring reproductive-metabolic balance. Future research should clarify inter-organ molecular mediators and validate autophagy-targeted strategies to advance personalized PCOS treatment."

Journal • Review • Hepatology • Inflammation • Metabolic Disorders • Metabolic Dysfunction-Associated Steatotic Liver Disease • Polycystic Ovary Syndrome

Safety of anagliptin/metformin combination tablets evaluated by non-inferiority between pre- and post-serum lactic acid levels in Japanese patients with type 2 diabetes and moderate renal impairment (AMELIO STUDY). (PubMed, J Diabetes Investig) - "This study demonstrates that the fixed-dose combination of anagliptin and metformin can be used safely in patients with type 2 diabetes complicated by moderate renal dysfunction. The advantage of this fixed-dose combination is also considered to be very large."

Head-to-Head • Journal • Diabetes • Metabolic Disorders • Nephrology • Renal Disease • Type 2 Diabetes Mellitus

Management of women with hirsutism in Kosovo. (PubMed, Postepy Dermatol Alergol) - "Oral contraceptives were prescribed to 33.3% of women, dexamethasone to 30.4% (alone or in combination with other medications), and metformin to 28.1% of cases. Early intervention and regular monitoring can prevent progression and provide significant relief. Ongoing research continues to offer hope for more effective, tailored therapies in the future."

Journal • Infertility • Sexual Disorders

Evaluation of the Chemo-preventive Effect of Combined Topical and Systemic Metformin on Oral Leukoplakia (clinicaltrials.gov) - P2 | N=34 | Recruiting | Sponsor: Cairo University

New P2 trial

GLP-1RA use improves outcomes post partial nephrectomy in T2DM patients with RCC: A TriNetX study. (PubMed, BJUI Compass) - "Patients prescribed GLP-1RAs were identified and matched in a 1:1 ratio with control patients who were not prescribed GLP-1RAs based on baseline characteristics, comorbidities, metformin and insulin prescription, and renal function laboratory values...Use of GLP-1RAs was associated with reduced incidence of 90-day postoperative complications, such as acute kidney injury, arrhythmia, readmission and ileus, potentially contributing to improved overall survival. These results align with ongoing studies investigating the broader benefits of the use of GLP-1RAs."

Journal • Acute Kidney Injury • Cardiovascular • Diabetes • Genito-urinary Cancer • Metabolic Disorders • Nephrology • Oncology • Renal Cell Carcinoma • Renal Disease • Solid Tumor • Type 2 Diabetes Mellitus

Exploring the role of the key gene TNFAIP3 between periodontitis and influenza A through bioinformatic analysis and molecular docking. (PubMed, PLoS One) - "Ultimately, machine learning algorithms identified TNFAIP3 as a common key gene for PD and IA, and further identified five drugs: Vemurafenib, Metformin, Dexamethasone, Tretinoin and Imatinib with potential for combined treatment of PD and IA. Our study reveals the shared mechanism and immune profile of TNFAIP3 as a key gene in PD and IA, which lays a theoretical foundation for future targeted therapies based on the shared mechanism of the two diseases."

Journal • Dental Disorders • Infectious Disease • Influenza • Periodontitis • Respiratory Diseases • TNFAIP3

Patients with tuberculosis and diabetes show altered clinical and biochemical parameters during anti-TB treatment. (PubMed, Sci Rep) - "Elevated hepatic enzymes in TB-DMnt may delay metformin initiation, suggesting a need to optimize timing post hepatic recovery, while the prevalence of hyponatremia underscores the need for routine electrolyte monitoring in TB patients with diabetes. The dysregulated lipid profile highlights cardiovascular risk that warrants routine monitoring. Despite metabolic challenges, effective TB treatment outcomes are achievable with comprehensive care."

Journal • Cardiovascular • Diabetes • Dyslipidemia • Heart Failure • Hypertriglyceridemia • Infectious Disease • Metabolic Disorders • Pulmonary Disease • Respiratory Diseases • Tuberculosis • Type 2 Diabetes Mellitus

Development and characterization of metformin hydrochloride hydrogels as potential wound dressings for diabetic foot ulcers. (PubMed, Int J Pharm) - "Compared with commercial drug-free hydrogel dressings, the optimized formulation showed superior mechanical strength, pH-modulating capacity, antibacterial activity against Escherichia coli and Pseudomonas aeruginosa, as well as attenuation of IL-6 expression in LPS-stimulated keratinocytes, indicating anti-inflammatory activity. Collectively, these findings highlight the early-stage potential of MET-loaded solid-sheet hydrogels as multifunctional dressings for chronic, low-exudate diabetic foot ulcers."

Journal • Diabetes • Infectious Disease • Metabolic Disorders • IL6

Myo-inositol Versus Metformin in Patients With Polycystic Ovarian Syndrome to Treat Obesity (clinicaltrials.gov) - P=N/A | N=60 | Completed | Sponsor: Muhammad Aamir Latif

New trial • Genetic Disorders • Obesity • Polycystic Ovary Syndrome

Prevention of Hearing Loss in the Cochlea of ​​Type 2 Diabetes Model Mice (ARO 2026) - "Preventive interventions included caloric restriction, administration of traditional Japanese herbal medicines (Bofu-tsusho-san and Dai-saiko-to), metformin, and SGLT2 inhibitors... The number of patients with diabetes mellitus is increasing worldwide due to changes in lifestyle and social environment. Diabetic patients are more likely to develop hearing loss (diabetes-related hearing loss), which often occurs from a relatively young age and significantly reduces quality of life (QOL). To clarify the mechanisms and effective preventive strategies of diabetic hearing loss, we investigated auditory function, cochlear histopathology, and preventive interventions using a type 2 diabetes mouse model."

Preclinical • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity • Otorhinolaryngology • Type 2 Diabetes Mellitus

Repurposing Pravastatin and Metformin for the Treatment and Prevention of Noise-Induced Hidden Hearing Loss in a Mouse Model (ARO 2026) - "ABR and DPOAE thresholds were assessed using two-way ANOVA with Tukey’s multiple comparisons, and wave-I amplitudes with two-way ANOVA followed by Dunnett’s test versus placebo; adjusted p values are reported. After completion with an expanded sample size across sexes, our data demonstrate that metformin plus pravastatin improves early auditory recovery after acoustic trauma. Effects were frequency- and sex-dependent, with combination therapy providing the most consistent protection in males and pravastatin contributing in females. Ongoing histology will clarify synaptic preservation underlying these outcomes and will be presented at February 2026 meeting."

Preclinical • Mood Disorders • Otorhinolaryngology • CTBP2

Gemcitabine Hydrochloride, Paclitaxel Albumin-Stabilized Nanoparticle Formulation, Metformin Hydrochloride, and a Standardized Dietary Supplement in Treating Patients With Pancreatic Cancer That Cannot be Removed by Surgery (clinicaltrials.gov) - P1 | N=21 | Active, not recruiting | Sponsor: City of Hope Medical Center | Trial completion date: Jan 2026 ➔ Dec 2026

Trial completion date • Oncology • Pancreatic Adenocarcinoma • Pancreatic Cancer • Solid Tumor

Evaluation of metformin's effect on 5-fluorouracil-induced cardiotoxicity through cellular protection. (PubMed, Daru) - "According to the present study results, metformin, through a reduction in oxidative stress, apoptosis, and mitochondrial malfunction, can have therapeutic potential in HCM cells toxicity induced by 5-FU."

IO biomarker • Journal • Cardiovascular • Congestive Heart Failure • Heart Failure • Metabolic Disorders • Oncology • BAX • BCL2 • CASP3

A network meta-analysis of randomized controlled trials evaluating the evidence of pharmacological agents and growth factors in the regeneration of bony defects in chronic periodontitis. (PubMed, BMC Oral Health) - "The study provides clinically relevant evidence supporting the adjunctive use of pharmacologic agents with PRF to optimize regenerative outcomes. Such combinations can improve bone fill and attachment gain, offering predictable benefits for patients with chronic periodontitis."

Journal • Retrospective data • Review • Dental Disorders • Infectious Disease • Periodontitis • Respiratory Syncytial Virus Infections

D2Rs Agonist Ropinirole Cooperates with Metformin to Modulate Thermogenesis and Ameliorate Obesity-Related Metabolic Disorders in Mice. (PubMed, Diabetes Metab J) - "However, the drug combination did not exhibit any enhanced effect on cell thermogenesis and these proteins in vitro, whereas combination of norepinephrine and metformin-induced an additive upregulation of mitochondrial function-related proteins. Furthermore, pharmacological blockade of the β3 adrenergic receptor inhibited the energy expenditure induced by the combination treatment, etc. Our study underscores the combination of metformin and ropinirole-induced an amplified effectiveness in treating obesity-related metabolic disorders is dependent on the dopamine-control sympathetic nerve activity, and metformin acts directly on BAT and iWAT to improve mitochondrial function, which offering a new perspective for future clinical co-treatment of metabolic disorders with these two drugs."

Journal • Preclinical • Diabetes • Dyslipidemia • Genetic Disorders • Metabolic Disorders • Obesity